This content is for educational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Read more.
Marsden360
Marsden360
Why refer to The Royal Marsden?
Transcript
The reason to refer to us is we've absolutely been leading the way in
delivering this. We were the first to set this up in country and deliver
this in the diagnostic setting as standard of care treatment.
We have led all of the research studies that have led to this being accepted as standard of care across the UK, and all of the use cases that now make it a standard of care for things such as earlier and faster diagnosis for lung cancer, pancreatic cancer and bowel duct cancer.
We're leading a huge number of research programs looking at other uses of ctDNA which gives us a wealth of experience in how to use this for the best outcome for patients.
And our molecular tumour board is absolutely unsurpassed in terms of the breadth of experience of all of the clinicians and scientists who take part in it, who have a long history of experience in both the diagnostic and the research setting in interpreting these reports and being able to decide what is relevant and what is not for patient care.
We have made a massive difference to so many patients with the use of this technology and being able to get faster diagnoses, more accurate diagnoses and to be able to get so many more patients on the best treatment for them first time.
So, if you want the absolute best treatment for your patient and to make sure that you are leaving no stone unturned in terms of how to personalise their treatment, you want to do the Marsden360.
We have led all of the research studies that have led to this being accepted as standard of care across the UK, and all of the use cases that now make it a standard of care for things such as earlier and faster diagnosis for lung cancer, pancreatic cancer and bowel duct cancer.
We're leading a huge number of research programs looking at other uses of ctDNA which gives us a wealth of experience in how to use this for the best outcome for patients.
And our molecular tumour board is absolutely unsurpassed in terms of the breadth of experience of all of the clinicians and scientists who take part in it, who have a long history of experience in both the diagnostic and the research setting in interpreting these reports and being able to decide what is relevant and what is not for patient care.
We have made a massive difference to so many patients with the use of this technology and being able to get faster diagnoses, more accurate diagnoses and to be able to get so many more patients on the best treatment for them first time.
So, if you want the absolute best treatment for your patient and to make sure that you are leaving no stone unturned in terms of how to personalise their treatment, you want to do the Marsden360.